NCT02690012View on ClinicalTrials.gov

Feasibility of Using an Integrated Consent Model to Compare Two Standard of Care Regimens for the Management of Hypomagnesemia From Anti-Cancer Therapies

NACompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

March 31, 2019

Study Completion Date

March 31, 2019

Conditions
Hypomagnesemia
Interventions
OTHER

Magnesium Oxide

Magnesium Oxide

OTHER

Magnesium Citrate

Magnesium Citrate

Trial Locations (1)

K1H8L6

The Ottawa Hospital Cancer Centre, Ottawa

Sponsors
All Listed Sponsors
lead

Ottawa Hospital Research Institute

OTHER